Improved diagnosis of idiopathic giant cell myocarditis and cardiac sarcoidosis by myocardial gene expression profiling

D. Lassner1†, U. Küh1,2†, C.S. Siegismund1, M. Rohde1, S. Elezkurtaj2, F. Escher1,2, C. Tschoöpe2, U.M. Gross1, W. Poller2, and H.-P. Schultheiss2

1Institute of Cardiac Diagnostics and Therapy, Moltkestrasse 31, D-12203 Berlin, Germany; 2Department of Cardiology and Pneumonology, Charité – University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany; and 3Institute of Pathology, Charité – University Medicine Berlin, Berlin, Germany

Received 5 June 2013; revised 5 February 2014; accepted 18 February 2014; online publish-ahead-of-print 24 March 2014

See page 2138 for the editorial comment on this article (doi:10.1093/eurheartj/ehu159)

Aims

Improvement of clinical diagnostics of idiopathic giant cell myocarditis (IGCM) and cardiac sarcoidosis (CS), two frequently fatal human myocardial diseases. Currently, IGCM and CS are diagnosed based on differential patterns of inflammatory cell infiltration and non-caseating granulomas in histological sections of endomyocardial biopsies (EMBs), after heart explantation or postmortem. We report on a method for improved differential diagnosis by myocardial gene expression profiling in EMBs.

Methods and results

We examined gene expression profiles in EMBs from 10 patients with histopathologically proven IGCM, 10 with CS, 18 with active myocarditis (MCA), and 80 inflammation-free control subjects by quantitative RT–QPCR. We identified distinct differential profiles that allowed a clear discrimination of tissues harbouring giant cells (IGCS, CS) from those with MCA or inflammation-free controls. The expression levels of genes coding for cytokines or chemokines (CCL20, IFNB1, IL6, IL17D; \( P < 0.05 \)), cellular receptors (ADIPOR2, CCR5, CCR6, TLR4, TLR8; \( P < 0.05 \)), and proteins involved in the mitochondrial energy metabolism (CPT1, CYB, DHODH; \( P < 0.05 \)) were deregulated in 2- to 300-fold, respectively. Bioinformatic analyses and correlation of the gene expression data with immunohistochemical findings provided novel information regarding the differential cellular and molecular pathomechanisms in IGCM, CS, and MCA.

Conclusion

Myocardial gene expression profiling is a reliable method to predict the presence of multinuclear giant cells in the myocardium, even without a direct histological proof, in single small EMB sections, and thus to reduce the risk of sampling errors. This profiling also facilitates the discrimination between IGCM and CS, as two different clinical entities that require immediate and tailored differential therapy.

Keywords

Idiopathic giant cell myocarditis • Cardiac sarcoidosis • Dendritic cells • Gene profiling • CCL20 • CCR6

Translational perspective:

Idiopathic giant cell myocarditis (IGCM) and cardiac sarcoidosis (CS), two frequently fatal human myocardial diseases, often present with similar clinical features. Current diagnostics is based on histological examination of endomyocardial biopsies (EMBs). Due to its focal appearance, a direct proof of multinuclear giant cells or sarcoid granulomas in EMB specimens is often unsuccessful in routine histology, but early and exact diagnosis is a prerequisite for an immediate and tailored therapy. The presented myocardial expression profiling facilitates the primary diagnosis and discrimination of IGCM and CS, even without a direct histological confirmation of focal multinucleated cells, and is suitable for monitoring of the treatment response.

1 These authors contributed equally to this work.

* Corresponding author. Tel: +49 30 8441 5540, Fax: +49 30 8441 5555, Email: info@ikdt.de

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com
Introduction

Cardiac inflammatory processes involving giant cells comprise a diverse group of disorders. The distinction between idiopathic giant cell myocarditis (IGCM), a life-threatening and rapidly progressing disease with fatal prognosis, and cardiac sarcoidosis (CS) remains particularly challenging and is frequently delayed until autopsy. Idiopathic giant cell myocarditis is regarded as a distinct clinical and pathological entity with exclusively cardiac manifestation and poor survival, whereas CS as a predominantly systemic disorder presents with less rapid progression of heart failure but nevertheless fatal outcome in patients with untreated heart involvement. Cardiac sarcoidosis is essentially a non-necrotizing process with gradual progression, whereas IGCM is associated with acute myocyte necrosis and extensive early scar formation.

Idiopathic giant cell myocarditis and CS with cardiac involvement present as acute myocarditis or progressing idiopathic heart failure, respectively and, because the pathogenetic causes take place at the cellular and subcellular levels, it is impossible to discriminate between both diseases or active lymphocytic myocarditis, respectively, by non-invasive clinical investigations including imaging methods. Endomycocardial biopsy (EMB) is the gold standard indicated in suspected myocarditis but has low sensitivity to exclude IGCM or necrotizing eosinophilic myocarditis, due to focal involvement of the myocardium. A definite diagnosis of CS with exclusion of all other causes of non-caseating granulomas and of IGCM can only be made by EMB but 70–80% of biopsies are non-diagnostic.

Since both multinuclear giant cells and granulomas are easily missed by conventional histological evaluation, an improved method to reliably identify IGCM despite of above described difficulties and independent from histology is desirable. During the last decade, gene expression profiling has been successfully introduced in clinical diagnoses. To date, there exists only one published approach to identify IGCM-specific genes but clinical information is limited due to the low sample numbers (2 controls vs. 2 IGCM) and the fact that biopsies have been taken from patients under immunosuppressive therapy. Immunosuppression is a condition which causes rapid reduction of myocardial inflammation.

Patients and methods

Patients

This retrospective study evaluated EMB specimens of 4738 consecutive patients with clinically suspected myocarditis or idiopathic dilated cardiomyopathy. The tissue samples were obtained between 2003 and 2011 to evaluate a possible origin of symptoms of moderate-to-severe heart failure in patients presenting different forms of myocarditis. The demographic data of all 20 patients are depicted in Table 1. The same holds true for clinical and demographic parameters such as LV-EF, LV-EDD, NYHA classification, gender, and age. The demographic data of all patients are depicted in Table 1. The age distribution of all 20 patients at the onset of histopathological confirmation of giant cells is shown in Supplementary material online, Figure S1.

Analysis of myocardial inflammation

The EMB diagnosis of myocarditis was based on histomorphologic criteria according to the Dallas Classification supplemented by quantitative immunohistochemical analyses. Histological evaluations were performed on paraffin sections of two to three EMBs using standard procedures, i.e. formaldehyde or RNA-later fixation, paraffin embedding, staining with haematoxylin & eosin, periodic acid Schiff stain, Elastica van Gieson stain, and azan stain. Immunohistochemical analyses were carried out on frozen sections (two EMBs) in order to allow the detection of additional inflammatory cell subsets with non-paraffin staining antibodies, e.g. CD11a (LFA-1), CD11b (MAC-1), CD45R0 (memory or activated lymphocytes), Perforin-positive cytotoxic lymphocytes, CD54 (ICAM-1), CD106 (VCAM-1) and HLA-I. Inflammatory cells and cell adhesion molecules were analysed using quantitative digital imaging analysis as reported earlier.

Nucleic acid isolation and reverse transcription to cDNA

Genomic DNA from EMBs (n = 2–3) was extracted by Puregene Mousetail Kit (Gentra, MN, USA). The detection of viral DNA was performed with primers specific for corresponding virus by nested PCR. Specificity of positive PCR products of viral genomes was confirmed by DNA sequencing. Total RNAs were isolated from EMBs (n = 2–3) using Trizol reagent (Invitrogen, Karlsruhe, Germany), treated with DNase (Peqlab, Erlangen, Germany) to remove any traces of genomic DNA and reverse transcribed to cDNA with the High Capacity Kit (Life Technologies, Darmstadt, Germany).

Preamplification and gene expression analysis

The cDNA of all patients was immediately transcribed at the time of the baseline biopsy and stored at −80 °C until use for gene expression analyses. The gene expression data of control patients were compared with those of patients presenting different forms of myocarditis. The demographic data are depicted in Table 1.

Differential gene expression was determined by QPCR of generated cDNAs. Due to limited amounts of myocardial cDNA, a preamplification within the 9-year interval of baseline analysis. For this study, patients without viral genomes detected in the routine molecular biological analysis and undetectable inflammation of heart muscle tissue were defined as inflammation-free control group (n = 80). Control patients were selected from the same time period accordingly. Clinically, IGCM and MCA patients presented with symptoms mimicking acute myocardial infarction including angina, ST-segment elevation, elevated creatine kinase or Troponin T/I and pro-BNP, and sudden onset of symptomatic heart failure including fatigue, reduced physical capacity, dyspnoea at rest or on exertion and new occurrence of global wall motion abnormalities. Fatigue, weakness, chest pain at rest or on exertion, dyspnoea on exertion, palpitations, reduced physical capacity, and progressive impairment of global systolic left ventricular function were the dominant persisting complaints of CS patients and controls.

Control patients complained for persisting symptoms of heart failure despite unremarkable EMB information.

Symptomatic heart failure medication including ACE inhibitors/ARB, beta blockers, diuretics, and aldosterone antagonists was not different between the four cohorts of patients (Table 1). The same holds true for clinical and demographic parameters such as LV-EF, LV-EDD, NYHA classification, gender, and age. The demographic data of all patients are depicted in Table 1. The age distribution of all 20 patients at the onset of histopathological confirmation of giant cells is shown in Supplementary material online, Figure S1.
Histological and immunohistological classification of patients

Histological features

Examples of the histological and immunohistological findings are given in Figure 1. In the virus and inflammation-free control group, regular histological structures and only few lymphocytes in the surrounding of capillaries were identified (Figure 1A). In MCA, necrotic myocytes adjacent to infiltrating lymphocytes and histiocytes were identified by cytoplasmic dissolution of fibrillar contractile structures (Figure 1B−D) which resembled myocytolysis bordering cellular infiltrates in IGCM (Figure 1B). Idiopathic giant cell myocarditis displayed a rather diffuse infiltration of cardiac tissue with a mixture of inflammatory cells, e.g. lymphocytes, macrophages, multinuclear giant cells, some eosinophiles, and disseminated necrosis of myocytes, whereas CS was characterized by a circumscribed process with non-caseating granulomas in which comparable cellular infiltrates, including multinuclear giant cells, were present while myocyte necroses were exclusively localized at the periphery of the inflamed areas. Fibrosis of granulomas could be observed in older foci of CS patients.

The most important feature to discriminate IGCM from CS resulted from the different histological patterns. In IGCM, this constituted a diffuse infiltration by T-lymphocytes, macrophages, or histiocytes and the presence of multinuclear giant cells with necrosis or apoptosis of neighbouring myocytes. Fibroblasts might be present, however, without a tendency to build granular structures. In CS, the inflammation was more focally distributed with collagen fibres that built up granular structures. Necrotic or apoptotic myocytes were predominantly present at the periphery of the inflammatory cell foci (Figure 1E and F). Examples of CD3- or CD11b-positive cells in an active stage of CS are depicted in Figure 1G and H. Patients were considered to have MCA, IGCM, or CS if one of the submitted samples met the criteria in histological or immunohistochemical analyses in EMBs without any proof in other organ tissues.

Distinctive gene expression profiles in myocarditis presenting giant cells

Aim of this EMB-based study was to identify a characteristic gene expression pattern in myocardial tissue that differentiates giant cells from giant cell negative and, of course, from inflammation-free tissue.

Differentially expressed genes encoded for cellular receptors including Toll-like receptors (TLRs), regulators of the immune response, and genes of the mitochondrial energy metabolism (Figure 2). Genes coding for distinct receptors (ADIPOR2, CCR5, CCR6, TLRs) expressed on cardiomyocytes, T-cells, and dendritic cells (DCs) were significantly dysregulated in comparison to the control cohort. Whereas the ADIPOR2 gene was up-regulated in CS (P < 0.05), genes coding for CCR5 and CCR6 on T-cells, and...
activated DCs were up-regulated in IGCM (Figure 2A). Toll-like receptor 8, an intracellular receptor on plasmacytoid DCs and monocytes, that responds to single-stranded RNA of viral origin and has been reported to become activated in autoimmune settings 18–20 was strongly overexpressed in IGCM (P, 0.001) suggesting activation of TLR8-dependent innate immune signalling (Figure 2A). In contrast to TLR8, the expression levels of TLR3, TLR4, and TLR9 were significantly suppressed in all inflammatory cardiomyopathies (Figure 2B).

The extensive infiltration of myocardial tissue by inflammatory cells may be responsible for the strong up-regulation of several key genes involved in the adaptive immune response (CCL20, FOXP3, IFNB1, IL6, IL10) (Figure 2C) in IGCM and was not detected in the other inflammatory disorders. This massive induction of CCL20 in conjunction with that of CCR5 and CCR6 (Figure 2A) is consistent with a particularly strong activation of DCs in IGCM. A similarly pronounced CCL20 up-regulation necessary to attract CCR6+ T lymphocytes to inflamed tissues has been reported in response to a microbial infection via synergistic effects of the pro-inflammatory cytokines IL1B and TNF.21,22

In giant cell arteritis (GCA), DCs mediate T helper 1 (Th1) and Th17 cell activation.22 Even though IL17D was significantly reduced in IGCM, expression of pro-inflammatory cytokines secreted by macrophages (IL1B, IL10, IL6, TNF) upon IL17 stimulation was elevated as shown for GCA (Figure 2C).22 It has been reported that TLR4 induces GCA via enhanced production of CCL20 followed by attraction of CCR6 positive, media-invasive T cells in an arteritis mouse model.23 In contrast, TLR4 was significantly suppressed in our human EMBs (Figure 2B).20,22

Cardiac sarcoidosis but not IGCM displayed a significant deregulation of CPT1 (P, 0.01), DHODH (P, 0.05), and CYB (P, 0.05). These genes coding for proteins of the mitochondrial respiratory complexes were not differentially expressed in MCA and controls (Figure 2D).

Due to their distinct differential expression, the obtained expression profiles suggest the presence of giant cells in small myocardial tissue samples even in the absence of unequivocal histopathologic evidence of these cells. Furthermore, genes (CPT1, IFNB1, IL17D, CYB, DHODH) that are differentially regulated between CS and IGCM facilitate their delimitation.

### Table 2: List of used gene expression test systems (Life Technologies)

<table>
<thead>
<tr>
<th>Nr.</th>
<th>Gene symbol</th>
<th>Gene name</th>
<th>Possible functions</th>
<th>Assay nr. Life Technologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>A4GALT</td>
<td>4-α-Galactosyltransferase</td>
<td>P-globoside, viral receptor</td>
<td>Hs00213726_m1</td>
</tr>
<tr>
<td>2</td>
<td>ADIPOR2</td>
<td>Adiponectin receptor 2</td>
<td>Adiponectin pathway</td>
<td>Hs0026105_m1</td>
</tr>
<tr>
<td>3</td>
<td>CCL20</td>
<td>Chemokine (C–C motif) ligand 20/MIP3 alpha</td>
<td>DCs, chemokine</td>
<td>Hs0101368_m1</td>
</tr>
<tr>
<td>4</td>
<td>CCR5</td>
<td>Chemokine (C–C motif) receptor 5</td>
<td>T-cell receptor</td>
<td>Hs00152917_m1</td>
</tr>
<tr>
<td>5</td>
<td>CCR6</td>
<td>Chemokine (C–C motif) receptor 6</td>
<td>T-cell receptor</td>
<td>Hs00171121_m1</td>
</tr>
<tr>
<td>6</td>
<td>CPT1</td>
<td>Carnitine palmitoyltransferase 1B (muscle)</td>
<td>Fatty acid oxidation</td>
<td>Hs00993896_g1</td>
</tr>
<tr>
<td>7</td>
<td>DHODH</td>
<td>Dihydro-orotat-dehydrogenase</td>
<td>Mitochondrial respiratory chain</td>
<td>Hs00361406_m1</td>
</tr>
<tr>
<td>8</td>
<td>FOXP3</td>
<td>Forkhead box P3</td>
<td>Regulatory T-cells</td>
<td>Hs00203958_m1</td>
</tr>
<tr>
<td>9</td>
<td>HPRT1</td>
<td>Hypoxanthine phosphoribosyltransferase 1</td>
<td>Housekeeping gene</td>
<td>Hs99999903_m1</td>
</tr>
<tr>
<td>10</td>
<td>IL10</td>
<td>IL10</td>
<td>Cytokine</td>
<td>Hs99999035_m1</td>
</tr>
<tr>
<td>11</td>
<td>IL17D</td>
<td>IL17D</td>
<td>Th17 immunoype</td>
<td>Hs00370528_m1</td>
</tr>
<tr>
<td>12</td>
<td>IL1B</td>
<td>IL1, β</td>
<td>Cytokine</td>
<td>Hs00174097_m1</td>
</tr>
<tr>
<td>13</td>
<td>IL23R</td>
<td>IL23 receptor</td>
<td>Th17 immunoype</td>
<td>Hs00322759_m1</td>
</tr>
<tr>
<td>14</td>
<td>IL6</td>
<td>IL6</td>
<td>Cytokine</td>
<td>Hs00174131_m1</td>
</tr>
<tr>
<td>15</td>
<td>IL6R</td>
<td>IL6 receptor</td>
<td>Cytokine receptor</td>
<td>Hs01075667_m1</td>
</tr>
<tr>
<td>16</td>
<td>IFNB1</td>
<td>Interferon β</td>
<td>Cytokine</td>
<td>Hs00277188_s1</td>
</tr>
<tr>
<td>17</td>
<td>ATP6</td>
<td>Mitochondrially encoded ATP synthase 6</td>
<td>Mitochondrial respiratory chain</td>
<td>Hs02596862_g1</td>
</tr>
<tr>
<td>18</td>
<td>CYB</td>
<td>Mitochondrially encoded cytochrome b</td>
<td>Mitochondrial respiratory chain</td>
<td>Hs02596867_s1</td>
</tr>
<tr>
<td>19</td>
<td>ND1</td>
<td>Mitochondrially encoded NADH dehydrogenase 1</td>
<td>Mitochondrial respiratory chain</td>
<td>Hs02596873_s1</td>
</tr>
<tr>
<td>20</td>
<td>ND4</td>
<td>Mitochondrially encoded NADH dehydrogenase 4</td>
<td>Mitochondrial respiratory chain</td>
<td>Hs02596876_g1</td>
</tr>
<tr>
<td>21</td>
<td>TGFB1</td>
<td>Transforming growth factor, β1</td>
<td>Cytokine</td>
<td>Hs00998133_m1</td>
</tr>
<tr>
<td>22</td>
<td>TLR3</td>
<td>TLR3</td>
<td>TLR</td>
<td>Hs00155078_m1</td>
</tr>
<tr>
<td>23</td>
<td>TLR4</td>
<td>TLR4</td>
<td>TLR</td>
<td>Hs01060206_m1</td>
</tr>
<tr>
<td>24</td>
<td>TLR7</td>
<td>TLR7</td>
<td>TLR</td>
<td>Hs00152971_m1</td>
</tr>
<tr>
<td>25</td>
<td>TLR8</td>
<td>TLR8</td>
<td>TLR</td>
<td>Hs00607866_mH</td>
</tr>
<tr>
<td>26</td>
<td>TLR9</td>
<td>TLR9</td>
<td>TLR</td>
<td>Hs00283251_m1</td>
</tr>
<tr>
<td>27</td>
<td>TNF</td>
<td>Tumour necrosis factor (TNF superfamily, member 2)</td>
<td>Cytokine</td>
<td>Hs00174128_m1</td>
</tr>
<tr>
<td>28</td>
<td>UQCR</td>
<td>Ubiquinol-cytochrome c reductase, complex III subunit XI</td>
<td>Mitochondrial respiratory chain</td>
<td>Hs00199138_m1</td>
</tr>
</tbody>
</table>

**Correlation of immunohistochemical markers with deregulated genes**

The immunohistochemical analysis of inflammatory cell populations and the expression of adhesion molecules showed significant...
**Figure 1** Histological findings in endomyocardial biopsies. A: Virus- and inflammation-free control. Few lymphocytes (Ly) near capillaries. H&E stain. B: MCA with widespread infiltration of lymphocytes, macrophages and necrosis or apoptosis of myocytes (N). H&E stain. C: IGCM: Lytic necrosis (N) or apoptosis of myocytes in the central area with dense cellular infiltration of lymphocytes and some macrophages or histiocytes, some eosinophiles and a multinuclear giant cell (GC) H&E stain. D: IGCM: In the center lytic necrosis or apoptosis of myocytes (M), in the surroundings infiltrates of lymphocytes (Ly) and some macrophages (Mph) or histiocytes, some eosinophiles (E) and a multinuclear giant cell (GC) H&E stain. E: Granuloma of CS with circumscribed infiltrate of lymphocytes (Ly), macrophages (Mph), multinuclear giant cell (GC) and fibroblasts producing collagen fibers stained red. Scar at the periphery of the focus (F). EvG stain. F: Multiple granulomas in CS with increasing sclerosis and fibrosis of the foci (F). Multinuclear giant cells, lymphocytes, macrophages and fibroblasts near myocytes (M). EvG stain. G: Granuloma of CS with multinuclear giant cells (GC), macrophages and lymphocytes. Immunohistological stain for CD3 positive cells (T-lymphocytes). In the periphery of the granuloma myocytes (M) partially on the way to necrosis or apoptosis. Positive lymphocytes with brown reaction product. H: Granuloma of CS immunohistology stain for CD 11b (MAC-1). Brown reaction product in the cytoplasm of activated macrophages. Multinuclear giant cells partially negative. Myocytes (M), multinuclear giant cells (GC).
differences between MCA, IGCM, and CS. The highest numbers of inflammatory infiltrates (CD3, LFA1, CD11b, CD45R0) and cell adhesion molecules (HLA-1, CD54/ICAM-1, CD106/VCAM1) were measured in IGCM (Table 3). These findings suggest that the different clinical features in the three inflammatory processes may not primarily be based on massive infiltration by inflammatory cells per se.\textsuperscript{10,13} Correlation analysis of myocardial gene expression with the immunohistochemical markers revealed a strong association of regulated genes with T-lymphocytes (CD3), activated T-cells (CD45R0), and Perforin-positive cytotoxic lymphocytes in CS. In contrast, gene expression in IGCM and MCA was mainly correlated with activated leukocytes and macrophages (LFA1, MAC-1) (Table 3). Such differences point to distinctions between CS, IGCM, and MCA with respect to the types and composition of the cellular infiltrates as well as the interactions of these cells with the myocardium.

In a second approach, the numbers of inflammatory cells detected by immunohistochemistry were correlated with the expression levels of deregulated genes (Table 3) in order to identify a possible correlation of individual cell types with specific genes. Of note, the correlation pattern of specific genes with corresponding inflammatory cells was different for IGCM, CS, MCA and controls (Table 3). These data again support the assumption that the origin as well as the cellular and molecular triggers of IGCM and CS are different and constitute distinct disease entities.

### Idiopathic giant cell myocarditis and cardiac sarcoidosis show different pathway regulation

The classification of intracellular and systemic pathways that are possibly involved in the pathogenesis of IGCM, CS, and MCA was

![Figure 2](https://academic.oup.com/eurheartj/article-abstract/35/32/2186/2481154)  
**Figure 2.** Cardiac gene expression shifts associated with presence of giant cells. Expression profiles of patients with active myocarditis (MCA), cardiac sarcoidosis (CS), and idiopathic giant cell myocarditis (IGCM) compared with controls for genes of cellular and Toll-like receptors (A), down-regulated Toll-like receptors (B), chemokines and cytokines (C), and energy metabolism (D). All expression values of controls are given as 100% and the others in relation to it. MCA vs. controls: *P < 0.05; **P < 0.01, CS vs. controls: +P < 0.05; +++P < 0.001, IGCM vs. controls: +P < 0.05; ++P < 0.01; +++P < 0.001, CS vs. IGCM: *P < 0.05; **P < 0.01.
performed by a bioinformatic approach using determined gene profiles and ingenuity pathway analysis software (Ingenuity, Redwood City, CA, USA). Based on the analysed gene set, 206 transcription factors, 1171 molecular functions, 7 top pathways, 393 associated genes, 51 canonical pathways, and 1317 disease-related functions were predicted (Supplementary material online, Table S1A–D).

Bioinformatic extraction of measured gene levels showed an activation of different transcription factors clustering MCA and CS in one group and IGCM in a second one (Supplementary material online, Table S1A). A comparable similarity was seen by predicted activated functions in myocardial inflammatory processes (Supplementary material online, Table S1B). The prediction of involved cellular networks combines both inflammatory disease harbouring giant cells in myocardium (CS, IGCM) and separate them from MCA (Supplementary material online, Table S1C). The complete separation of all three disease entities is made by extraction of disease-related functions (Supplementary material online, Table S1D).

The combined analysis of gene expression profile characteristics, immunohistochemical markers, and bioinformatic predictions of cellular pathways and associated functions, clearly demonstrates that MCA, IGCM, and CS have to be considered as distinct entities with few overlapping features.
Table 3  Correlation of immunohistochemical markers with gene expression in endomyocardial biopsies

<table>
<thead>
<tr>
<th>Disease group</th>
<th>CD3/mm²</th>
<th>LFA1/mm²</th>
<th>Perforin/mm²</th>
<th>Mac1/mm²</th>
<th>CD45R0/mm²</th>
<th>HLA1 (%AFb)</th>
<th>CD54 (%AF)</th>
<th>CD106 (%AF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>5.7</td>
<td>14</td>
<td>1</td>
<td>28.4</td>
<td>17.4</td>
<td>7.5</td>
<td>2.1</td>
<td>0.04</td>
</tr>
<tr>
<td>MCA</td>
<td>26.2</td>
<td>57.5</td>
<td>2.9</td>
<td>49.79</td>
<td>51.9</td>
<td>9</td>
<td>2.9</td>
<td>0.11</td>
</tr>
<tr>
<td>CS</td>
<td>9.4</td>
<td>26.4</td>
<td>1.3</td>
<td>43.75</td>
<td>24.6</td>
<td>11.6</td>
<td>3.6</td>
<td>0.095</td>
</tr>
<tr>
<td>IGCM</td>
<td>141.5</td>
<td>308</td>
<td>2.5</td>
<td>178.3</td>
<td>214.5</td>
<td>14.5</td>
<td>12.4</td>
<td>0.5</td>
</tr>
</tbody>
</table>

**Significant differences of disease groups by immunohistochemical markers (P-value at least < 0.05)**

- **CS vs. controls**: P < 0.05  
- **CS vs. MCA**: P < 0.001  
- **CS vs. IGCM**: P < 0.001  
- **IGCM vs. Controls**: P < 0.001  
- **MCA vs. controls**: P < 0.001  

**Significant correlation of gene expression to immunohistochemical markers (P-value at least < 0.05)**

- **Controls**: ATP6, CCL20, CCR5, CPT1, IL6R, IL17D, ND4, TGFβ  
- **MCA**: ATP6, CCL20, CCR5, CYB, IL6R, IL10, IL23R, TLR3, TGFβ  
- **CS**: ATP6, CCL20, CCR5, CYB, IL6R, IL10, IL23R, TLR3, TGFβ  
- **IGCM**: ATP6, CCL20, CCR5, CYB, IL6R, IL10, IL23R, TLR3, TGFβ  
- **Overall**: ATP6, CCL20, CCR5, CYB, IL6R, IL10, IL23R, TLR3, TGFβ

---

*a* Number of positively stained cells per mm² digitally analysed myocardial tissue.  
*b* Area fraction (percentage in % of positively stained, digitally analysed myocardial tissue).
Discussion

Idiopathic giant cell myocarditis and cardiac involvement of sarcoidosis (CS) often escape diagnosis until autopsy or transplantation because of their unspecific clinical presentation and focal appearance which both contribute to the considerable sampling error in the histologic analysis. Both diseases cause severe heart failure with fatal outcome if untreated but development of cardiac impairment in IGCM occurs much faster than in CS. This demands a reliable diagnostic method that allows an unambiguous separation of IGCM from CS.

In this retrospective study, 20 consecutive patients (10 IGCM, 10 CS) with multinucleated giant cells in their myocardium were identified out of those patients that were submitted to our institution for routine EMB diagnostics. Mean age of patients with IGCM and CS was 52.1 (± 6.7) and 46.6 (± 6.6) years, respectively. The reason for the higher mean age of patients in our study, when compared with earlier publications, could be caused by the fact that we analysed EMB samples but no explanted hearts of autopsy material from patients with end-stage disease.1,2 Idiopathic giant cell myocarditis is a condition with short median survival from onset of symptoms.1–3 The younger IGCM patients are more likely to die before the clinical diagnostics including EMB is completed and therefore are often diagnosed postmortem.

Since IGCM is a rapidly progressing myocardial disease with a high early mortality of ~40% within the first 2–4 weeks it demands combined immunosuppression with anti-thymocyte globulin, ciclosporin, and prednisolon immediately after diagnostic confirmation in order to improve short- and long-term prognosis. Due to the often fatal outcome, the prognostic influence of immunosuppression, however, remains poorly known.5 Cardiac involvement occurs in 20–27% of sarcoidosis patients in the USA, ~11% in Finland and may be as high as 58% in Japan with a high mortality of nearly 50% in 5 years.3,24,25 The diagnosis, although circumstantial, is strongly suspected if cardiac manifestation occurs in a patient with multi-systemic sarcoidosis. However, when cardiac dysfunction is the only manifestation of sarcoidosis, the diagnosis is frequently not entertained. Only 40–50% of patients with CS diagnosed at autopsy have the diagnosis made during their lifetime and in 37% of those patients no clinical signs or symptoms of the disease were present. This is in line with our observation that the first hints of a sarcoidosis were obtained from EMB in 70% of our positive patients. Systolic heart failure due to cardiac involvement in CS often responds to monotherapy with corticosteroids or other immunosuppressive agents.6,26

Despite the limitations of EMB with respect to sensitivity, the confirmation of IGCM and isolated CS confined to the heart solely depends on histology.11,12 The sensitivity of EMB for non-caseating granulomas is low, usually <20%, and a consequence of patchy myocardial involvement which frequently involves the interventricular septum and the left ventricle. In the absence of detectable granulomas, it is difficult to distinguish CS from IGCM.1,2 since both diseases possess giant cells and are associated with ventricular tachycardia or heart block. Due to their focal appearance, a direct proof of giant cells demands multiple biopsies and examination of all sections of the multiple tissue samples, but even then focally distributed multinuclear giant cells are generally detected in not >2–6 sections of a biopsy. Of note, the giant cells were detected in only 1 of 5–10 histologically examined specimens in the reported IGCM patients. In this view, the probability that a second independent biopsy with giant cells has been extracted for gene expression profiling has to be considered very low. Although we cannot exclude this in single rare cases, we assume that the changed gene expression profiles represent alterations within the entire myocardium and also apart from areas with infiltrating giant cells as shown by the simultaneous analysis of three EMB specimens of a single patient (Supplementary material online, Figure S3).

In CS deregulated genes affect the cellular receptor ADIPOR2 and CCL20 as well as components of the mitochondrial respiratory chain such as CPT1, CYB, or DHODH. In contrast, IGCM gene expression is deregulated for genes of immune and TLRs CCR5, CCR6, TLRB and to distinct acquired immune response genes such as CCL20, FOXP3, IFNB1, IL6, IL10, and IL17D.

In IGCM, the pronounced increase of CCR5 and CCR6 may be mediated by the massive T-cell infiltration21,22 and the consequent up-regulation of the CCR6 ligand CCL20 and pro-inflammatory cytokines IL6 and IL10 by macrophages, DCs, multinucleated giant cells, or epitheloid cells. Similarly, TLR8 ligands result in a synergistic release of pro-inflammatory mediators which also promote the activation of IL17-producing T cells.28 Last but not least, TLRB is an intracellular receptor that responds to single-stranded viral RNA18–20 and the massive up-regulation of TLRB in IGCM could be caused by a viral component associated with this disease entity.3 DHODH and CPT1, two genes of the mitochondrial respiratory chain, are good discriminators of the two forms of sarcoidosis presenting with multinuclear giant cells, IGCM and CS. DHODH is a key enzyme involved in pyrimidine biosynthesis and inhibition of DHODH leads to activation of p53 and induction of p53-dependent apoptosis.29 Down-regulation of IL17D, as seen in IGCM, may be caused by an inhibition of this enzyme that also reduces the proliferation of lymphocytes and thereby blocks the production of IL-17 by lymphocytes in inflammatory diseases.30,31 CPT1 is the rate-limiting enzyme for fatty acid β-oxidation in adipocytes. Cardiac sarcoidosis may display lower expression of immune response genes since the isoform CPT1A exerts anti-inflammatory effects by suppression of pro-inflammatory adipokines such as TNFα and IL6.32

Some patients displayed slightly variable patterns in their gene expression levels, but expression profiles allow a clear cut distinction of MCA, IGCM, and CS (Figure 2A–D). Although gene expression levels do not necessarily correlate with the protein levels, this is no obstacle for the use of the above described gene expression profiles as diagnostic tools. Reported differences in gene profiles allow for the first time a prediction of giant cells in myocardium even without their direct histological proof. Additionally, the identified gene profiles clearly discriminate between inflammation-free controls and MCA, IGCM, or CS. This provides a valuable additional diagnostic information, providing that no immunosuppressive treatment has been administered before.

Recently, published data have compared an only limited number of healthy controls with two IGCM patients under immunosuppressive treatment. Since other pronounced inflammatory conditions such as MCA or CS have not been taken into consideration and immunosuppression is known to rapidly alter gene expression profiles, the obtained gene expression data are of limited clinical relevance.3 In untreated patients, deregulated gene levels are persisting and some gene expression differences are even increasing during follow-up.
(data not shown). Consequently, diagnostic gene profiling has to be applied before initiation of any immunosuppression in order to get reliable clinical information. The aim of the presented study was the identification of specific diagnostic gene profiles in EMBs rather than to elucidate information on mechanisms of IGM and CS that are correlated with biopsy independent parameters, e.g., cytokines in plasma fractions. This molecular approach provides additional information on the aetiology and pathogenesis of IGM and CS in addition to histologic information facilitating therapy decision-making according to recent consensus statements for EMB diagnostics of both diseases. The aim of the presented study was the identification of specific diagnostic gene profiles in EMBs rather than to elucidate information on mechanisms of IGM and CS that are correlated with biopsy independent parameters, e.g., cytokines in plasma fractions. This molecular approach provides additional information on the aetiology and pathogenesis of IGM and CS in addition to histologic information facilitating therapy decision-making according to recent consensus statements for EMB diagnostics of both diseases. The generation of valid gene expression data from single small biopsy specimen requires optimal specimen procurement, adequate sample storage, and preamplification techniques for specific gene sets with reverse transcription of cellular RNA into cDNA immediately after biopsy processing. The RNA amount of one to two EMBs is sufficient to perform reliable and repeatable expression profiling studies including multiple genes, also in archived samples.

Conclusion

Direct histological proof of multinuclear giant cells or sarcoid granulomas successes rarely in routine histology. Differential myocardial expression profiling using a set of 10–15 of 27 altered genes is suitable to differentiate giant cell myocarditis from active lymphocytic myocarditis (MCA) and facilitates the discrimination between IGM and CS. Correlation and bioinformatic analysis demonstrates the pronounced differences between CS, IGM, and MCA regarding the types and composition of the cellular infiltrates and their influence on myocardial gene expression.

Supplementary material

Supplementary material is available at European Heart Journal online.

Acknowledgement

For their excellent technical assistance, we thank Mrs K. Winter, S. Ochmann, C. Seifert, E. Hertel, M. Willner, and A. Kallet, Berlin, Germany.

Funding

This work was supported by grants of the German Research Foundation (DFG), Transregional Collaborative Research Centre ‘Inflammatory Cardiomyopathy – Molecular Pathogenesis and Therapy’ (SFB TR19, Z1), and two grants of the Federal Ministry of Education and Research (BMBF, Germany) for KMU innovative program (No. 616 0315296, 03161414).}

Conflict of interests: D.L., H.P.S., M.R., and U.K. have a pending patent (DE 20102101557.0) including presented gene profiles.

References


